The Latest Breaking News from Gilead

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

"If trust is lost it's like a house of cards—and currently X lacks trust from both its audiences and its B2B partners."

JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too.

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

The Succession star rages against inequality; all aboard Netflix’s Victorian steamship horror; Hongkongers turn to violence; and The Handmaid’s Tale is back on track

Biopharmaceutical giant Gilead Sciences (GILD) reported better-than-expected third-quarter earnings and sales and raised its full-year guidance. Analysts see immense growth potential in the company’s HIV and oncology franchises, which should boost its performance in the upcoming quarters. Given its strong earnings, high profitability, discounted valuation, and attractive dividend, we think…